国产精品99一区二区三_免费中文日韩_国产在线精品一区二区_日本成人手机在线

Biosimilar developed for chronic rheumatic immune disease in China

Source: Xinhua| 2019-09-03 10:34:09|Editor: Yamei
Video PlayerClose

BEIJING, Sept. 3 (Xinhua) -- Chinese researchers have developed a biosimilar to treat ankylosing spondylitis.

Ankylosing spondylitis is a type of chronic rheumatic immune disease encroaching spinal joints and peripheral joints, resulting in spine malformation in extreme cases. The disease affects about 0.3 percent of the Chinese population.

The research team, linking 20 domestic medical centers including Tsinghua University School of Medicine, conducted analysis on patients between 18 and 65 years old.

Patients were randomly assigned in a one to one ratio to receive either 40 mg of IBI303 or adalimumab as a subcutaneous injection every 2 weeks until week 22, according to a paper recently published in the journal Lancet Rheumatology.

The results showed therapeutic equivalence of IBI303 and adalimumab in ankylosing spondylitis treatment, said the paper. The efficacy, safety and immunogenicity of the drugs are highly similar.

IBI303 could be a treatment option for patients with ankylosing spondylitis in China.

The country issued a trial technical guideline in 2015 to boost biosimilar drugs development and evaluation.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011103261383608201
主站蜘蛛池模板: 灵宝市| 遵义市| 清丰县| 获嘉县| 德令哈市| 东乡县| 兴城市| 永泰县| 元阳县| 兰西县| 双鸭山市| 宁城县| 金沙县| 桦南县| 抚州市| 郯城县| 芷江| 时尚| 镇巴县| 祁门县| 临夏市| 红河县| 海南省| 房产| 延庆县| 韶关市| 久治县| 泾川县| 巴青县| 江津市| 淳化县| 河间市| 江山市| 和田县| 万载县| 若羌县| 安仁县| 乌鲁木齐市| 家居| 海淀区| 松潘县|